Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227 Meeting Abstract
| Authors: | Paz-Ares, L. G.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; Pluzanski, A.; Ramalingam, S. S.; Brahmer, J. R.; Borghaei, H.; O'Byrne, K. J.; Hellmann, M. D.; Memaj, A.; Bushong, J.; Tran, P.; Reck, M. |
| Abstract Title: | Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227 |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604310 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.9016 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9016 -- Source: Wos |
